The Vesalius Research Center (VRC) has focused since 15 years its research interests on unraveling the molecular basis of neuro-vascular biological processes and diseases, and translating these genetic insights in therapeutic concepts – with the ultimate aspiration to develop novel treatments
Herestraat 49, box 912 | T: +32 16 373 235 |
No front page content has been created yet.
On Wednesday June 26th, there will be a Metabolism Mini Symposium hosted by Peter Carmeliet and Sarah-Maria Fendt.
Following speakers give a lecture:
For the new Laboratory of Endothelial Molecular Biology we are looking for two postdoctoral scientsits:
Are you interested in cutting edge research on cancer metabolism.
We zijn op zoek naar een enthousiaste gedreven laboratoriumtechnoloog. De onderzoeksgroep focust op onderzoek van neurodegeneratieve aandoeningen, meer in het bijzonder motor neuron degeneratie en hersenberoertes.
We are seeking highly motivated, creative and independent, postdoctoral researchers with a track record of peer-reviewed publications. Candidates should have a strong background in cancer and neurobiology, be skilled in molecular and cellular biology methods and must have received, or are soon expecting, a PhD degree.
We are seeking a highly motivated scientist who is willing to join a team of international researchers investigating the interaction between metabolism and hypoxia.
28 February 2013
A medulloblastoma is a malignant brain tumor that occurs primarily in children and is currently untreatable. Peter Carmeliet and his team (VIB-KU Leuven) joined forces with scientists at Massachusetts General Hospital in Harvard to study the role of the placental growth factor (PIGF) in the growth of this brain tumor. They demonstrated that blocking PIGF inhibits the growth and metastasis of this cancer. This creates hope for a new therapy for the treatment of children with a medulloblastoma, with fewer side effects than the current treatments.
